Radiotherapy dose-dependently sensitized low mutational burden KrasG12D x p53−/− sarcoma lines to anti-CTLA-4 plus anti-PD-1 by increasing its immunogenicity through radiation-induced neoantigen production [132]. The gene discussed is CTLA4; the disease is sarcoma.